Session » SLE – Etiology & Pathogenesis Poster II

Date: Tuesday, November 12, 2019

Time: 9:00AM-11:00AM

Meeting: 2019 ACR/ARP Annual Meeting

9:00AM-11:00AM: Abstract Number: 2029

Aberrant H3K9me3 Modification in Promoter Region Up-regulates cAMP Response Element Modulator Alpha in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2022

Analysis of Gene Expression from Systemic Lupus Erythematosus Synovium Reveals Unique Pathogenic Mechanisms

9:00AM-11:00AM: Abstract Number: 2025

Ancestry Influences the Gene Expression Profile in Systemic Lupus Erythematosus and Contributes to Transcriptomic Heterogeneity in Lupus Patients

9:00AM-11:00AM: Abstract Number: 2038

Antibodies to Malondialdehyde-acetaldehyde (MAA) Protein Adduct as a Biomarker for Cardiovascular Manifestations in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2040

BATF2 Contributes to Interferon Dysregulation in SLE Keratinocytes

9:00AM-11:00AM: Abstract Number: 2027

Dysregulation of Granulopoiesis in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2032

Enhanced IFN a Production and STING Pathway in Monocytes in Systemic Lupus Erythematosus Is Suppressed by the Inhibition of mTOR Activation

9:00AM-11:00AM: Abstract Number: 2041

Epigenome-wide Association Study Reveals Differential DNA Methylation in Systemic Lupus Erythematosus Patients with a History of Ischemic Heart Disease

9:00AM-11:00AM: Abstract Number: 2044

Expression of SLAMF6 and Its Functional Significance in Podocytes of Lupus Nephritis: Report with Consideration Based on the Results of Microarray Analysis in Podocytes of MRL/lpr Mice

9:00AM-11:00AM: Abstract Number: 2023

Gene-Expression Analysis of Male and Female SLE Patients Reveals Candidate Pathogenic Pathways

9:00AM-11:00AM: Abstract Number: 2024

Genetics of Longitudinal Kidney Function in Children and Adults with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2039

High Prevalence and Disease Correlation of Autoantibodies Against p40 Encoded by Long Interspersed Nuclear Elements (LINE-1) in SLE

9:00AM-11:00AM: Abstract Number: 2021

Higher Genetic Risk Load in Patients with More Diverse Manifestations in a Korean Systemic Lupus Erythematosus Cohort

9:00AM-11:00AM: Abstract Number: 2034

Identification of IL-17+ and IL-10+ TCRαβ+ CD4- CD8- Double Negative (DN) T Cell Subsets in Lupus-prone Mice and Patients with SLE and Their Significance in Predicting Renal Involvement

9:00AM-11:00AM: Abstract Number: 2028

Inhibited Expression of Hematopoietic Progenitor Kinase 1 in Tfh Cells Contributes to Autoimmunity in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2031

Interferon Alpha Promotes Caspase-Dependent Apoptosis Independently of Reactive Oxygen Species in Ultraviolet B-Exposed Keratinocytes

9:00AM-11:00AM: Abstract Number: 2042

Intestinal Microbiota Alters Th1/Th17 Balance but Is Dispensable for the Development of Systemic Autoimmune Disease in BXD2 Mice

9:00AM-11:00AM: Abstract Number: 2033

IRAK4 Inhibition Suppresses TLR7, TLR9, and SLE Serum-Induced IFNA Production in Primary Human Plasmacytoid Dendritic Cells

9:00AM-11:00AM: Abstract Number: 2043

Large Joint Arthritis in Systemic Lupus Erythematosus Is Characterized by TH17 Cells Rather Than B Cell Accumulation

9:00AM-11:00AM: Abstract Number: 2026

MicroRNA-27a Can Contribute to Interferon Signatures in Systemic Lupus Erythematosus via the Suppression of Tripartite Motif-containing Protein 27

9:00AM-11:00AM: Abstract Number: 2036

Mitochondrial DNA: A Potential Trigger of Cyclic GMP-AMP Synthase Activation in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2046

NMR Spectroscopy Reveals Alterations of Urinary Acetate and Citrate Levels Following Cyclophosphamide Therapy in Patients with Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 2045

RNA Sequencing of Plasma and Urine-derived Extracellular Vesicles from Lupus Nephritis Patients Identifies Disease-associated Small RNA Signatures and Putative Therapeutic Targets

9:00AM-11:00AM: Abstract Number: 2030

Staphylococcus Aureus Colonization Is Increased on Lupus Skin Lesions and Is Promoted by Interferon-Mediated Barrier Disruption

9:00AM-11:00AM: Abstract Number: 2035

Systemic Lupus Erythematosus (SLE) Is Caused by Expanded DOCK8-Positive Autoantibody-Inducing CD4 T (aiCD4 T) Cell

9:00AM-11:00AM: Abstract Number: 2037

Understanding Langerhans Cell ADAM17 Levels in Systemic Lupus Erythematosus: Potential Contributor to Photosensitivity

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].